IMVT logo

Immunovant Inc. (IMVT)

$34.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IMVT

Market cap

$7.07B

EPS

-2.55

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.948215

Price on IMVT

Previous close

$35.05

Today's open

$34.71

Day's range

$33.87 - $34.84

52 week range

$21.86 - $45.42

Profile about IMVT

CEO

Eric Venker

Employees

315

Headquarters

Durham, NC

Exchange

Nasdaq Global Select

Shares outstanding

206947758

Issue type

Common Stock

IMVT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IMVT

Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know

Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 11, 2026

news preview

What Immunovant (IMVT) Said on Its Q2 Earnings Call

Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt Gline cautioned that the LISRAYA results covered only about five weeks on the market and included a boost from pharmacy inventory.

news source

MarketBeat • Nov 9, 2026

news preview

Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript

Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.

news source

Seeking Alpha • Nov 9, 2026

news preview

Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study

Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).

news source

Benzinga • Nov 9, 2026

news preview

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026

IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in Period 2 continued to increase, reaching 80.0% ACR50 and 52.5% ACR70 at Week 28 FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial All other clinical development timelines remain on track Roivant will host a live conference call and webcast at 8:00 a.m.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

news source

GlobeNewsWire • Oct 21, 2026

news preview

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

news source

PRNewsWire • Oct 12, 2026

news preview

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Oct 11, 2026

news preview

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.

news source

PRNewsWire • Sep 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Immunovant Inc.

Open an M1 investment account to buy and sell Immunovant Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IMVT on M1